Michael Marcotte
Michael Marcotte has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Etienne Sibille
Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
4 shared publications - Thomas Damien Prevot
Centre for Addiction and Mental Health
4 shared publications - Dishary Sharmin
Department of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA
2 shared publications - James Minton Cook
Department of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA
2 shared publications - Yeunus Mian
Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53201, United States
2 shared publications - Akiko Sumitomo
Centre for Addiction & Mental Health (CAMH), Toronto ON
1 shared publication
Latest Publications
- Open Access
The Aging Brain Matrix: Cross-Species Evidence Linking FREM3 to Brain and Cognitive Aging
The human extracellular-matrix-related FREM3 gene is strongly age-dependent, enriched in age- sensitive excitatory long-range-projecting neurons, and implicated in neurodegenerative diseases. To establish the first translationally relevant causal evidence for the gene’s roles in brain structure and cognition, we developed an excitatory-neuron-specific Frem3 conditional knockout mouse model ( Frem3 -cKO) and computed genetically regulated expression of FREM3 ( FREM3 - GReX) in humans, enabling convergent neurostructural and cognitive characterizations. Frem3 - cKO mice showed widespread lower global and regional brain volume in middle age vs young adulthood, consistent with drastic age-dependent volume loss absent in wildtype mice. These effects were strongest in cognitively relevant cortical regions and paralleled by lower cognitive performance. In humans, lower FREM3- GReX was associated with lower total surface area, which further mediated an indirect link to lower cognitive performance across multiple age- sensitive domains. We provide the first translationally relevant cross-species evidence supporting a key role for FREM3/Frem3 in maintaining brain and cognitive health across aging.
Open AccessThe Aging Brain Matrix: Cross-Species Evidence Linking FREM3 to Brain and Cognitive Aging
The human extracellular-matrix-related FREM3 gene is strongly age-dependent, enriched in age- sensitive excitatory long-range-projecting neurons, and implicated in neurodegenerative diseases. To establish the first translationally relevant causal evidence for the gene’s roles in brain structure and cognition, we developed an excitatory-neuron-specific Frem3 conditional knockout mouse model ( Frem3 -cKO) and computed genetically regulated expression of FREM3 ( FREM3 - GReX) in humans, enabling convergent neurostructural and cognitive characterizations. Frem3 - cKO mice showed widespread lower global and regional brain volume in middle age vs young adulthood, consistent with drastic age-dependent volume loss absent in wildtype mice. These effects were strongest in cognitively relevant cortical regions and paralleled by lower cognitive performance. In humans, lower FREM3- GReX was associated with lower total surface area, which further mediated an indirect link to lower cognitive performance across multiple age- sensitive domains. We provide the first translationally relevant cross-species evidence supporting a key role for FREM3/Frem3 in maintaining brain and cognitive health across aging.
- Open Access
- 13 June 2025
- Published by Wiley in Hippocampus
- Vol. 35 (4) , e70019
Chronic α5‐ GABA ‐A Receptor Potentiation Promotes Mouse Adult Hippocampal Neurogenesis
Several lines of evidence implicate adult hippocampal neurogenesis (AHN) in cognitive functions, in mood‐ and anxiety‐related behaviors, and in the therapeutic effects of antidepressants. Augmenting α5‐γ‐Aminobutyric acid type A (GABAA) receptor function has shown neurotrophic effects in stress and aged models, but its impact on mouse AHN remains unknown. Adult male 129S6/SvEvTac mice ( n = 30 total) were treated for 6 weeks with GL‐II‐73, an α5‐GABAA‐R‐positive allosteric modulator (α5‐PAM) [30 mg/kg, per os, (P.O.)] or fluoxetine, a prototypical selective serotonin reuptake inhibitor known to increase AHN (18 mg/kg, P.O.). Proliferation in the subgranular zone of the dentate gyrus (DG) was assessed by the level of Ki67, a marker of dividing cells; survival of the young neurons was assessed by retention of the 5‐Bromo‐2´‐Deoxyuridine (BrdU) nucleotide analog injected 2 weeks before sacrifice. Finally, maturation of young adult‐born neurons was evaluated by measuring the fraction of BrdU‐positive cells that are also DCX and/or NeuN‐positive, capturing overall maturation and speed of maturation. Similarly to fluoxetine, a chronic treatment with GL‐II‐73 stimulated all stages of AHN, significantly increasing neuronal progenitor proliferation, survival of adult‐born granule cells, and maturation of young neurons in the DG of the hippocampus. Chronic treatment with GL‐II‐73, a α5‐GABAA‐R‐positive allosteric modulator, increased AHN, including cellular proliferation, survival, and maturation of newborn neurons, to levels comparable to fluoxetine.
- 13 June 2025
- Published by Wiley in Hippocampus
- Vol. 35 (4) , e70019
Open AccessChronic α5‐ GABA ‐A Receptor Potentiation Promotes Mouse Adult Hippocampal Neurogenesis
Several lines of evidence implicate adult hippocampal neurogenesis (AHN) in cognitive functions, in mood‐ and anxiety‐related behaviors, and in the therapeutic effects of antidepressants. Augmenting α5‐γ‐Aminobutyric acid type A (GABAA) receptor function has shown neurotrophic effects in stress and aged models, but its impact on mouse AHN remains unknown. Adult male 129S6/SvEvTac mice ( n = 30 total) were treated for 6 weeks with GL‐II‐73, an α5‐GABAA‐R‐positive allosteric modulator (α5‐PAM) [30 mg/kg, per os, (P.O.)] or fluoxetine, a prototypical selective serotonin reuptake inhibitor known to increase AHN (18 mg/kg, P.O.). Proliferation in the subgranular zone of the dentate gyrus (DG) was assessed by the level of Ki67, a marker of dividing cells; survival of the young neurons was assessed by retention of the 5‐Bromo‐2´‐Deoxyuridine (BrdU) nucleotide analog injected 2 weeks before sacrifice. Finally, maturation of young adult‐born neurons was evaluated by measuring the fraction of BrdU‐positive cells that are also DCX and/or NeuN‐positive, capturing overall maturation and speed of maturation. Similarly to fluoxetine, a chronic treatment with GL‐II‐73 stimulated all stages of AHN, significantly increasing neuronal progenitor proliferation, survival of adult‐born granule cells, and maturation of young neurons in the DG of the hippocampus. Chronic treatment with GL‐II‐73, a α5‐GABAA‐R‐positive allosteric modulator, increased AHN, including cellular proliferation, survival, and maturation of newborn neurons, to levels comparable to fluoxetine.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Improvement of Cognitive Functions And Neurotrophic Effects through by Α5‐GABAA Receptor Positive Allosteric Modulation in Animal Models of Risk for Alzheimer’s Disease
Background: Reduced GABA/somatostatin (SST) signaling is reported in psychiatric, stress‐related and neurodegenerative disorders. SST+ interneurons from cortical layers and the hippocampus inhibit the dendrites of excitatory neurons, largely through α5‐containing GABAA receptors (α5‐GABAAR). Recently, we showed that an α5‐positive allosteric modulator (α5‐PAM) alleviates working memory deficits and reverses neuronal atrophy in old mice. We then started to investigate the behavioral and neurotrophic effects of this α5‐PAM in animal models of aging, chronic stress, and β‐amyloid load, as risk factor for developing Alzheimer’s disease.Method: Three studies are presented, with ∼12 mice/group, 50% female: 1) Young C57BL6 subjected to unpredictable chronic mild stress (UCMS) to induce cognitive deficits. 2) 22 month‐old C57BL6 developing an age‐related cognitive decline. 3) 5xFAD transgenic mice with progressive amyloid‐related cognitive decline. In all studies, efficacy of chronic administration of GL‐II‐73 (30mg/kg, p.o, for 4 weeks) at rescuing cognitive deficits across 3 domains was assessed. Working memory was assessed in an alternation task, spatial memory in the water maze, and cognitive flexibility in a set‐shifting assay. Brains were then stained using Golgi‐Cox technique (n = 4brain/group; 8cell/brain) for quantification of dendritic length and spine density in the prefrontal cortex and hippocampus (NeuroLucida).Result: Chronic treatment in all models reversed cognitive deficits across domains (ps<0.01), with a strong effect on working memory. Chronic treatment also significantly reversed UCMS‐, age‐, or amyloid‐induced dendritic shrinkage and reduction of spine density at apical and basal dendrites (p<0.001 in PFC and CA1).Conclusion: Together, results support that selective α5 targeting of GABAA receptors overcomes chronic stress‐, aging‐, or amyloid‐related cognitive deficits and detriments in neuronal morphology. This represents the first intervention targeting the GABAergic system to have a symptomatic and disease‐modifying therapeutic potential in a transdiagnostic manner. This could represent a major avenue for clinical development for patients suffering from cognitive deficits across brain disorders.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Open AccessImprovement of Cognitive Functions And Neurotrophic Effects through by Α5‐GABAA Receptor Positive Allosteric Modulation in Animal Models of Risk for Alzheimer’s Disease
Background: Reduced GABA/somatostatin (SST) signaling is reported in psychiatric, stress‐related and neurodegenerative disorders. SST+ interneurons from cortical layers and the hippocampus inhibit the dendrites of excitatory neurons, largely through α5‐containing GABAA receptors (α5‐GABAAR). Recently, we showed that an α5‐positive allosteric modulator (α5‐PAM) alleviates working memory deficits and reverses neuronal atrophy in old mice. We then started to investigate the behavioral and neurotrophic effects of this α5‐PAM in animal models of aging, chronic stress, and β‐amyloid load, as risk factor for developing Alzheimer’s disease.Method: Three studies are presented, with ∼12 mice/group, 50% female: 1) Young C57BL6 subjected to unpredictable chronic mild stress (UCMS) to induce cognitive deficits. 2) 22 month‐old C57BL6 developing an age‐related cognitive decline. 3) 5xFAD transgenic mice with progressive amyloid‐related cognitive decline. In all studies, efficacy of chronic administration of GL‐II‐73 (30mg/kg, p.o, for 4 weeks) at rescuing cognitive deficits across 3 domains was assessed. Working memory was assessed in an alternation task, spatial memory in the water maze, and cognitive flexibility in a set‐shifting assay. Brains were then stained using Golgi‐Cox technique (n = 4brain/group; 8cell/brain) for quantification of dendritic length and spine density in the prefrontal cortex and hippocampus (NeuroLucida).Result: Chronic treatment in all models reversed cognitive deficits across domains (ps<0.01), with a strong effect on working memory. Chronic treatment also significantly reversed UCMS‐, age‐, or amyloid‐induced dendritic shrinkage and reduction of spine density at apical and basal dendrites (p<0.001 in PFC and CA1).Conclusion: Together, results support that selective α5 targeting of GABAA receptors overcomes chronic stress‐, aging‐, or amyloid‐related cognitive deficits and detriments in neuronal morphology. This represents the first intervention targeting the GABAergic system to have a symptomatic and disease‐modifying therapeutic potential in a transdiagnostic manner. This could represent a major avenue for clinical development for patients suffering from cognitive deficits across brain disorders.
- Open Access
- 14 June 2022
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 47 (9) , 1608-1619
Symptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress
Chronic stress is a risk factor for Major Depressive Disorder (MDD), and in rodents, it recapitulates human behavioral, cellular and molecular changes. In MDD and after chronic stress, neuronal dysfunctions and deficits in GABAergic signaling are observed and responsible for symptom severity. GABA signals predominantly through GABAA receptors (GABAA-R) composed of various subunit types that relate to downstream outcomes. Activity at α2-GABAA-Rs contributes to anxiolytic properties, α5-GABAA-Rs to cognitive functions, and α1-GABAA-Rs to sedation. Therefore, a therapy aiming at increasing α2- and α5-GABAA-Rs activity, but devoid of α1-GABAA-R activity, has potential to address several symptomologies of depression while avoiding side-effects. This study investigated the activity profiles and behavioral efficacy of two enantiomers of each other (GL-II-73 and GL-I-54), separately and as a racemic mixture (GL-RM), and potential disease-modifying effects on neuronal morphology. Results confirm GL-I-54 and GL-II-73 exert positive allosteric modulation at the α2-, α3-, α5-GABAA-Rs and α5-containing GABAA-Rs, respectively, and separately reduces immobility in the forced swim test and improves stress-induced spatial working memory deficits. Using unpredictable chronic mild stress (UCMS), we show that acute and chronic administration of GL-RM provide pro-cognitive effects, with mild efficacy on mood symptoms, although at lower doses avoiding sedation. Morphology studies showed reversal of spine density loss caused by UCMS after chronic GL-RM treatment at apical and basal dendrites of the PFC and CA1. Together, these results support using a racemic mixture with combined α2-, α3-, α5-GABAA-R profile to reverse chronic stress-induced mood symptoms, cognitive deficits, and with anti-stress neurotrophic effects.
- 14 June 2022
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 47 (9) , 1608-1619
Open AccessSymptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress
Chronic stress is a risk factor for Major Depressive Disorder (MDD), and in rodents, it recapitulates human behavioral, cellular and molecular changes. In MDD and after chronic stress, neuronal dysfunctions and deficits in GABAergic signaling are observed and responsible for symptom severity. GABA signals predominantly through GABAA receptors (GABAA-R) composed of various subunit types that relate to downstream outcomes. Activity at α2-GABAA-Rs contributes to anxiolytic properties, α5-GABAA-Rs to cognitive functions, and α1-GABAA-Rs to sedation. Therefore, a therapy aiming at increasing α2- and α5-GABAA-Rs activity, but devoid of α1-GABAA-R activity, has potential to address several symptomologies of depression while avoiding side-effects. This study investigated the activity profiles and behavioral efficacy of two enantiomers of each other (GL-II-73 and GL-I-54), separately and as a racemic mixture (GL-RM), and potential disease-modifying effects on neuronal morphology. Results confirm GL-I-54 and GL-II-73 exert positive allosteric modulation at the α2-, α3-, α5-GABAA-Rs and α5-containing GABAA-Rs, respectively, and separately reduces immobility in the forced swim test and improves stress-induced spatial working memory deficits. Using unpredictable chronic mild stress (UCMS), we show that acute and chronic administration of GL-RM provide pro-cognitive effects, with mild efficacy on mood symptoms, although at lower doses avoiding sedation. Morphology studies showed reversal of spine density loss caused by UCMS after chronic GL-RM treatment at apical and basal dendrites of the PFC and CA1. Together, these results support using a racemic mixture with combined α2-, α3-, α5-GABAA-R profile to reverse chronic stress-induced mood symptoms, cognitive deficits, and with anti-stress neurotrophic effects.
- 30 November 2015
- Published by Wiley in Prenatal Diagnosis
- Vol. 36 (2) , 142-147
Intrauterine fetal demise after prenatal diagnosis of congenital heart disease: assessment of risk
Objectives: Elective deliveries in fetal congenital heart disease (CHD) attempt to balance fetal and neonatal risk with the goal of optimizing overall outcome. However, the magnitude of the risk for intrauterine fetal demise (IUFD) is unclear. This study aimed to (1) determine the rate of IUFD and (2) identify fetal risk factors associated with IUFD.Methods: Retrospective review of pregnancies complicated by CHD between 1998 and 2010. Data were collected regarding pregnancy outcome, extracardiac anomalies (ECA), genetic and cardiac diagnoses, severity of valve regurgitation, gestational age at birth and birth weight. Fisher's exact test and odds ratios were used to compare outcomes between groups.Results: A total of 501 pregnancies analyzed resulted in 445 live births, 22 IUFD, 16 terminations and 18 unknown outcomes. Amongst IUFD, 27% had a genetic diagnosis, 50% had an ECA and 27% had severe valve regurgitation. IUFD odds increased threefold with ECA and sevenfold with severe valve regurgitation. IUFD occurred in 1.2% without risk factors.Conclusions: IUFD in fetuses with CHD is associated with ECA, genetic syndromes and severe valve regurgitation. In absence of these fetal characteristics, the occurrence of IUFD is low, although it remains higher than in fetuses without CHD. © 2015 John Wiley & Sons, Ltd.
- 30 November 2015
- Published by Wiley in Prenatal Diagnosis
- Vol. 36 (2) , 142-147
Intrauterine fetal demise after prenatal diagnosis of congenital heart disease: assessment of risk
Objectives: Elective deliveries in fetal congenital heart disease (CHD) attempt to balance fetal and neonatal risk with the goal of optimizing overall outcome. However, the magnitude of the risk for intrauterine fetal demise (IUFD) is unclear. This study aimed to (1) determine the rate of IUFD and (2) identify fetal risk factors associated with IUFD.Methods: Retrospective review of pregnancies complicated by CHD between 1998 and 2010. Data were collected regarding pregnancy outcome, extracardiac anomalies (ECA), genetic and cardiac diagnoses, severity of valve regurgitation, gestational age at birth and birth weight. Fisher's exact test and odds ratios were used to compare outcomes between groups.Results: A total of 501 pregnancies analyzed resulted in 445 live births, 22 IUFD, 16 terminations and 18 unknown outcomes. Amongst IUFD, 27% had a genetic diagnosis, 50% had an ECA and 27% had severe valve regurgitation. IUFD odds increased threefold with ECA and sevenfold with severe valve regurgitation. IUFD occurred in 1.2% without risk factors.Conclusions: IUFD in fetuses with CHD is associated with ECA, genetic syndromes and severe valve regurgitation. In absence of these fetal characteristics, the occurrence of IUFD is low, although it remains higher than in fetuses without CHD. © 2015 John Wiley & Sons, Ltd.